B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion

No abstract is available for this paper.

• Publication year

  1999

• Venue

  Nature Medicine

• Publication date

  1999-12-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/70932PMID 10581077
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Other functions, other genes: alternative activation of antigen-presenting cells.

  1999cited by this paper
• ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28

  1999cited by this paper
• ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28

  1999cited by this paper
• Requirement of CD28-CD86 co-stimulation in the interaction between antigen-primed T helper type 2 and B cells.

  1997cited by this paper
• Interleukin-10 promotes activation-induced cell death of SLE lymphocytes mediated by Fas ligand.

  1997cited by this paper
• Co-stimulation in T cell responses.

  1997cited by this paper
• T cell clonal anergy.

  1997cited by this paper
• CD28/B7 system of T cell costimulation.

  1996cited by this paper
• CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells

  1996cited by this paper
• CTLA-4 ligation blocks CD28-dependent T cell activation [published erratum appears in J Exp Med 1996 Jul 1;184(1):301]

  1996cited by this paper
• Costimulation by CD48 and B7-1 induces immunity against poorly immunogenic tumors

  1996cited by this paper
• CD28 and apoptosis.

  1995cited by this paper
• Identification of residues in the V domain of CD80 (B7-1) implicated in functional interactions with CD28 and CTLA4

  1995cited by this paper
• Both Extracellular Immunoglobin-like Domains of CD80 Contain Residues Critical for Binding T Cell Surface Receptors CTLA-4 and CD28 (*)

  1995cited by this paper
• B7-1 and B7-2 do not deliver identical costimulatory signals, since B7-2 but not B7-1 preferentially costimulates the initial production of IL-4.

  1995cited by this paper
• T cell clonal anergy.

  1994cited by this paper
• Immunoglobulin fold characteristics of B7–1 (CD80) and B7–2 (CD86)

  1994cited by this paper
• Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors.

  1994cited by this paper
• The tissue distribution of the B7-2 costimulator in mice: abundant expression on dendritic cells in situ and during maturation in vitro

  1994cited by this paper
• Costimulation of tumor-reactive CD4+ and CD8+ T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma.

  1994cited by this paper
• B70 antigen is a second ligand for CTLA-4 and CD28

  1993cited by this paper
• Costimulation of T cells for tumor immunity.

  1993cited by this paper
• Interleukin-10.

  1993cited by this paper
• Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation.

  1993cited by this paper
• Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4.

  1992cited by this paper

• MYC at the tumor–immune interface: mechanisms of immune escape and immunotherapy resistance

  2026cites this paper
• The IRF transcription factor family in type I interferon-mediated antiviral immunity and associated diseases

  2026cites this paper
• Innovative combinatory approaches with dendritic cell-based vaccines: bridging preclinical insights and clinical challenges

  2026cites this paper
• A new synthetic route for the preparation of programmed cell death ligand 1 inhibitor: ARB-272572

  2026cites this paper
• isMap – immunological synapse map analysis program

  2026cites this paper
• Prediction of neoadjuvant therapy efficacy in gastric cancer: the interplay between biomarkers and radiomics and its potential for clinical translation

  2026cites this paper
• Emerging Biomaterials Blocking PD‐1/PD‐L1 Pathway for Cancer Therapy

  2026cites this paper
• The role of programmed cell death 1 in autoimmune diseases: mechanisms and therapeutic implications

  2026cites this paper
• Immunotherapeutic advances in pediatric neuroblastoma: Overcoming resistance through biomarker-guided combinations.

  2026cites this paper
• Nanomedicine-driven strategies for CD8+ T cell enhancement in Cancer immunotherapy

  2026cites this paper
• Targeting PD-L1-CMTM6 interactions in myeloid cells triggers PD-L1 degradation and enhances cytotoxic T-cell expansion

  2025cites this paper
• PD-1/PD-L1 pathway relieves incision induced acute postoperative pain via inhibiting the neuroinflammation in dorsal root ganglion of rats

  2025cites this paper
• Dual targeting of PD-1/PD-L1 and iL-33/ST2 signalling pathways: a promising approach in breast cancer immunotherapy

  2025cites this paper
• Radiosynthesis and preclinical evaluation of [99mTc]Tc-HYNIC–durvalumab for immuno-SPECT imaging of PD-L1 expression in tumor models

  2025cites this paper
• Immune checkpoint inhibitors for the treatment of solid tumors and lymphoma in the past 26 years (2000–2025)

  2025cites this paper
• Transcriptome profiling of peripheral blood mononuclear cells from highly susceptible adult cattle infected with a virulent strain of Babesia bovis

  2025cites this paper
• Porphyromonas gingivalis outer membrane vesicles promote oral tumorigenesis through suppressing innate immune surveillance.

  2025cites this paper
• Role of PD-L1 in Regulatory T Cell-Mediated Suppression of Corneal Neovascularization.

  2025cites this paper
• Tipping the balance: the PD1-axis as modulator in chronic inflammatory demyelinating polyneuropathy.

  2025cites this paper
• Synergy of oncolytic adenovirus and immune checkpoint inhibitors: transforming cancer immunotherapy paradigms

  2025cites this paper
• Phase IB Study of Avelumab and Whole Brain Radiotherapy (WBRT) in Patients with Leptomeningeal Disease (LMD) from Solid Tumors: Results and Molecular Analyses.

  2025cites this paper
• Tislelizumab in conjunction with chemotherapy for the treatment of nasal metastasis from lung squamous cell carcinoma: a case report and literature review

  2025cites this paper
• Advances in PD-1 and CTLA-4 dual-target immunotherapy for ovarian cancer

  2025cites this paper
• NKAIN1 expression relates to the immune evasion and prognosis of gastric cancer

  2025cites this paper
• DETECTION OF HUMAN PD-1 ON T-CELLS USING A FUSION PROTEIN CONSISTING OF AN ANTI-PD-1 SINGLE CHAIN VARIABLE FRAGMENT LINKED TO SUPERFOLDER GFP.

  2025cites this paper
• Roles of the phagocytosis checkpoint in radiotherapy

  2025cites this paper
• Systemic chemotherapy in metastatic TNBC polarizes effector T cell differentiation

  2025cites this paper
• TREM2 facilitates gastric cancer progression and immune evasion via inhibiting TRIM21-mediated STAT1 degradation in tumor-associated macrophages

  2025cites this paper
• Structural insights into the impacts of non-synonymous single nucleotide polymorphisms in CD274 gene on the PD-1/PD-L1 interaction: An in silico approach.

  2025cites this paper
• Bibliometric analysis of immunotherapy for esophageal cancer: 2004-2024

  2025cites this paper
• STAM2-mediated fine-tuning of PD-L1 secretion via small extracellular vesicles in OSCC.

  2025cites this paper
• Programmed Death-Ligand 1 in Renal Allografts With Antibody-Mediated Rejection.

  2025cites this paper
• PD-L1 and the dawn of modern cancer immunotherapy

  2025cites this paper
• Polyunsaturated fatty acid-induced metabolic exhaustion and ferroptosis impair the anti-tumour function of MAIT cells in MASLD.

  2025cites this paper
• Association between periodontitis and gastrointestinal cancer risk and prognosis: evidence from a nested case–control study in Southwest China

  2025cites this paper
• PILRα on tumor cells interacts with the T cell surface protein CD99 to suppress antitumor immunity

  2025cites this paper
• Comparative analysis of PD-L1 expression and tumor-infiltrating lymphocytes between primary breast cancer and matched metastatic lesions: implications for immunotherapy

  2025cites this paper
• Exploring AI tools and multi-omics for precision medicine in lung cancer therapy.

  2025cites this paper
• Novel Protein Adjuvant Activating Innate IFN-γ and IL-18 Expression and Inducing Rejection of Implanted Colorectal Cancer Following Immunotherapy Using This Adjuvant in Mice

  2025cites this paper
• Targeted Inhibition of Tumor Extracellular Vesicle Secretion Improving the Anti‐Tumor Immunity of Lymph Node‐Targeted Vaccines

  2025cites this paper
• Immune Checkpoint Inhibitors (ICI) in Urological Cancers: A New Modern Era, but Not Generally Applied

  2025cites this paper
• Application of Immune Checkpoint Inhibitors in Cancer

  2025cites this paper
• The clinicopathological and prognostic significances of CMTM6 and PD-L1 expression in breast cancer

  2025cites this paper
• Regulation of PD-L1 Expression by SAHA-Mediated Histone Deacetylase Inhibition in Lung Cancer Cells

  2025cites this paper
• Securing the Language of Life: Inheritable Watermarks from DNA Language Models to Proteins

  2025cites this paper
• Combination of PD-1/PD-L1 and CTLA-4 inhibitors in the treatment of cancer – a brief update

  2025cites this paper
• Parkin modulates the hepatocellular carcinoma microenvironment by regulating PD-1/PD-L1 signalling

  2025cites this paper
• Discovery and characterization of two anti-PD-1 antibodies with a unique binding mechanism to human PD-1

  2025cites this paper
• Fatal Myocarditis Following Adjuvant Immunotherapy: A Case Report and Literature Review

  2025cites this paper
• Unlocking the mystery of the PD-1/PD-L1 axis: beyond the checkpoint hype

  2025cites this paper
• Therapeutic targeting of tumour-associated macrophage receptors

  2025cites this paper
• PD-L1 importance in malignancies comprehensive insights into the role of PD-L1 in malignancies: from molecular mechanisms to therapeutic opportunities

  2025cites this paper
• Advancements in immunotherapy for gastric cancer: Unveiling the potential of immune checkpoint inhibitors and emerging strategies.

  2025cites this paper
• Modulation of N-glycosylation in the PD-1: PD-L1 axis as a strategy to enhance cancer immunotherapies.

  2025cites this paper
• Mechanisms of Resistance to Anti-PD-1 Immunotherapy in Melanoma and Strategies to Overcome It

  2025cites this paper
• Immunohistochemical expression of PDL1 and Ki67 in glioma and its correlation with treatment and overall survival.

  2025cites this paper
• Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Non–Small Cell Lung Cancer: AMBER Part 2B

  2025cites this paper
• Multiregional CT Features Improve Prediction of Immunotherapy Response in Advanced Melanoma

  2025cites this paper
• Progress in the design of ascorbic acid derivative-mediated drug delivery

  2025cites this paper
• Structure and function of therapeutic antibodies approved by the US FDA in 2024

  2025cites this paper
• Novel GPU Engines for Virtual Screening of Giga-Sized Libraries Identify Inhibitors of Challenging Targets

  2025cites this paper
• Intelligent bacterial platform induces programmed death-ligand 1 lysosomal degradation to enhance antitumor immunity.

  2025cites this paper
• Alternative Splicing Events and Differently Expressed Genes During Peak Mortality in Large Yellow Croaker (Larimichthys crocea) Infected with Scuticociliate

  2025cites this paper
• Targeting HER2 in Gastroesophageal Cancer: A New Appetite for an Old Plight

  2025cites this paper
• Small molecules targeting immune checkpoint proteins for cancer immunotherapy: a patent and literature review (2020–2024)

  2025cites this paper
• Therapeutic Applications of Programmed Death Ligand 1 Inhibitors in Small Cell Lung Cancer

  2025cites this paper
• Immune checkpoint inhibitor-associated myocarditis: a review of current state of knowledge

  2025cites this paper
• CTLA-4—two pathways to anti-tumour immunity?

  2025cites this paper
• From Bench to Bladder: The Rise in Immune Checkpoint Inhibition in the Treatment of Non-Muscle Invasive Bladder Cancer

  2025cites this paper
• Biomarkers in lung cancer treatment.

  2025cites this paper
• Gut microbiota affects PD-L1 therapy and its mechanism in melanoma

  2025cites this paper
• Second-Line Systemic Therapies in Metastatic Renal Cell Carcinoma: Current Insights and Future Directions

  2025cites this paper
• Programmed cell death protein 1 in cancer cells

  2025cites this paper
• Transient intracellular expression of PD-L1 and VEGFR2 bispecific nanobody in cancer cells inspires long-term T cell activation and infiltration to combat tumor and inhibit cancer metastasis

  2025cites this paper
• Strategies to Design and Optimize Artificial Antigen‐Presenting Cells for T Cell Expansion in Cancer Immunotherapy

  2025cites this paper
• TIM-3 teams up with PD-1 in cancer immunotherapy: mechanisms and perspectives

  2025cites this paper
• Programmed Death-1 Ligand 1 Domain Organization, Signaling Motifs, and Interactors in Cancer Immunotherapy

  2025cites this paper
• PD-1 is conserved from sharks to humans: new insights into PD-1, PD-L1, PD-L2, and SHP-2 evolution

  2025cites this paper
• Tumor aneuploidy as a prognostic and predictive biomarker in immune checkpoint blockade

  2025cites this paper
• Beyond the Limit: MYC Mediates Tumor Immune Escape

  2025cites this paper
• Intrinsic PDL1 Signaling Modulates TGFBI‐Mediated Growth Suppression in Lung Adenocarcinoma

  2025cites this paper
• Improvement of the Anticancer Efficacy of PD‐1/PD‐L1 Blockade: Advances in Molecular Mechanisms and Therapeutic Strategies

  2025cites this paper
• Neuronal PD-L1 suppression attenuates ischemic stroke injury via PD-1/RFX1 axis-mediated microglial polarization

  2025cites this paper
• Identification and bioactivity of a programmed death-ligand 1 homologue in large yellow croaker (Larimichthys crocea).

  2025cites this paper
• Oncolytic Viruses Reshape PD‐1/PD‐L1 Signaling: Mechanisms and Clinical Synergy With Immune Checkpoint Blockade

  2025cites this paper
• Changes in tumor and cardiac metabolism upon immune checkpoint

  2024cites this paper
• Beyond peptides: Unveiling the design strategies, structure activity correlations and protein-ligand interactions of small molecule inhibitors against PD-1/PD-L1.

  2024cites this paper
• Fc Effector Function of Immune Checkpoint Blocking Antibodies in Oncology

  2024cites this paper
• Cancer Biomarkers and Precision Oncology: A Review of Recent Trends and Innovations

  2024cites this paper
• In situ editing of tumour cell membranes induces aggregation and capture of PD-L1 membrane proteins for enhanced cancer immunotherapy

  2024cites this paper
• Common biological processes and mutual crosstalk mechanisms between cardiovascular disease and cancer

  2024cites this paper
• Exploring the interplay between inflammation and male fertility

  2024cites this paper
• A comprehensive review of immune checkpoint inhibitors for cancer treatment.

  2024cites this paper
• Is modulation of immune checkpoints on glioblastoma-infiltrating myeloid cells a viable therapeutic strategy?

  2024cites this paper
• Innovative theranostic hydrogels for targeted gastrointestinal cancer treatment

  2024cites this paper
• Development of a Competitive Nutrient-Based T-Cell Immunotherapy Designed to Block the Adaptive Warburg Effect in Acute Myeloid Leukemia

  2024cites this paper
• The branched N-glycan of PD-L1 predicts immunotherapy responses in patients with recurrent/metastatic HNSCC

  2024cites this paper
• Therapeutic implications for the PD-1 axis in cerebrovascular injury

  2024cites this paper
• Research progress of CD80 in the development of immunotherapy drugs

  2024cites this paper
• Ultra-high dose rate (FLASH) carbon ion irradiation inhibited immune suppressive protein expression on Pan02 cell line

  2024cites this paper